

A range of univariate sensitivity analyses have been explored

Sensitivity analyses	Description	Abbreviated
SA01	Base case	Base case
SA02	Amgen STARs costing	Amgen STARs
SA03	Amgen NMA results	Amgen NMA
SA04	Amgen STARs costings and NMA results	Amgen STARs+NMA
SA05	No HRQoL step change for naive to experienced	No naive util step
SA06	SCC permanent utility effect of the average P1–P5 decrement	SCC ongoing mean
SA07	SCC permanent utility effect of the maximum P1–P5 decrement	SCC ongoing max.
SA08	No general mortality	No gen. mortality
SA09	5-year horizon	5-year horizon
SA10	2-year horizon	2-year horizon
SA11	vdHOUT utility multipliers	vd Hout utility
SA12	QoL impact SAEs ONJ and renal cohort average survival, not the measured trial duration	SAE P1 +
SA13	Excluding SAEs	No SAE
SA14	No general discontinuations	No gen. discs.
SA15	No discontinuations	No discs.
SA16	AG TTF functional form from NAIVE for breast and prostate	TTF form AG naive
SA17	AG TTF functional form all patients for breast, prostate and OSTL	TTF form AG all patients

These are presented for the four cancer groupings: breast, prostate and OST including lung (OSTL). They are also presented for the three patient groups of all, naive and experienced, coupled with the split between applying the pooled HRs and RRs and the SRE-specific HRs and RRs for breast prostate and OSTL. The summaries that follow all show the net impact of denosumab on total amounts. The costs reported are the total costs including SRE costs and SAE costs; for example, the cost associated with BSC excluding PAS is the additional cost of using denosumab compared with BSC. These sensitivity analyses are presented only for the analyses that apply the pooled HRs and RRs. The parallel sensitivity analyses that present them for the analyses that apply the SRE experience subgroup-specific HRs and RRs are available on demand from the AG.

The probabilistic analyses were run over 2000 iterations. As a cross-check the ALL PATIENT probabilistic modelling was re-run with 10,000 iterations, with results being near identical to those of the run with 2000 iterations.

Univariate sensitivity analyses: breast cancer

Breast	BSC		BSC		BSC		BSC		Zoledronic acid		Zoledronic acid	
	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
All patients												
Base case	£6242	£4292	-0.988	0.027	£229,547	£157,829	£1707	-£243	-0.211	0.007	£245,264	Dominant
Amgen STARs	£6623	£4673	-0.988	0.027	£243,559	£171,841	£1782	-£168	-0.211	0.007	£255,996	Dominant
Amgen NMA	£6324	£4374	-0.922	0.025	£257,431	£178,053	£1705	-£245	-0.213	0.007	£242,776	Dominant
Amgen STARs+NMA	£6683	£4733	-0.922	0.025	£272,032	£192,655	£1781	-£170	-0.213	0.007	£253,470	Dominant
No naive util step	£6242	£4292	-0.988	0.017	£366,760	£252,172	£1707	-£243	-0.211	0.005	£362,999	Dominant
SCC ongoing mean	£6242	£4292	-0.988	0.033	£189,204	£130,090	£1707	-£243	-0.211	0.008	£208,302	Dominant
SCC ongoing max.	£6242	£4292	-0.988	0.035	£179,091	£123,137	£1707	-£243	-0.211	0.009	£198,682	Dominant
No gen. mortality	£6277	£4316	-0.996	0.027	£228,819	£157,307	£1717	-£245	-0.213	0.007	£244,512	Dominant
5-year horizon	£6102	£4204	-0.935	0.025	£239,758	£165,176	£1670	-£229	-0.199	0.007	£256,441	Dominant
2-year horizon	£4781	£3319	-0.653	0.016	£291,409	£202,319	£1309	-£153	-0.139	0.004	£308,247	Dominant

Breast	BSC		BSC		BSC		BSC		Zoledronic acid		Zoledronic acid		Zoledronic acid	
	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	SREs	QALYs
All patients														
vd Hout utility	£6242	£4292	-0.988	0.025	£249,169	£171,320	£1707	-£243	-0.211	0.006	£266,094	ICER including	-0.211	0.006
SAE P1+	£6242	£4292	-0.988	0.026	£242,970	£167,058	£1707	-£243	-0.211	0.013	£134,378	ICER including	-0.211	0.013
No SAE	£6276	£4300	-1.001	0.028	£224,711	£153,953	£1773	-£203	-0.214	0.006	£291,955	ICER including	-0.214	0.006
No gen. discs.	£11,493	£7912	-1.841	0.046	£251,628	£173,216	£3167	-£414	-0.400	0.012	£259,902	ICER including	-0.400	0.012
No discs.	£11,744	£8085	-1.883	0.047	£252,493	£173,819	£3237	-£422	-0.409	0.012	£260,510	ICER including	-0.409	0.012
TTF form AG naive	£6235	£4285	-0.994	0.028	£225,904	£155,252	£1707	-£243	-0.211	0.007	£244,209	ICER including	-0.211	0.007
TTF form AG all	£6147	£4197	-1.060	0.030	£205,611	£140,382	£1687	-£263	-0.227	0.008	£222,101	ICER including	-0.227	0.008

Breast	BSC		BSC		BSC		BSC		Zoledronic acid		Zoledronic acid		Zoledronic acid	
	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS
Base case	f6308	f4358	-0.962	0.035	f181,092	f125,109	f1747	-f203	-0.186	0.008	f209,345	Zoledronic acid		
Amgen STARS	f6674	f4724	-0.962	0.035	f191,585	f135,602	f1812	-f138	-0.186	0.008	f217,069	Zoledronic acid		
Amgen NMA	f6432	f4482	-0.863	0.031	f210,330	f146,564	f1745	-f205	-0.189	0.008	f206,251	Zoledronic acid		
Amgen STARS+NMA	f6764	f4814	-0.863	0.031	f221,185	f157,419	f1810	-f140	-0.189	0.008	f213,963	Zoledronic acid		
No naive util step	f6308	f4358	-0.962	0.018	f358,586	f247,732	f1747	-f203	-0.186	0.005	f386,508	Zoledronic acid		
SCC ongoing mean	f6308	f4358	-0.962	0.040	f157,346	f108,704	f1747	-f203	-0.186	0.009	f187,157	Zoledronic acid		
SCC ongoing max.	f6308	f4358	-0.962	0.042	f150,985	f104,309	f1747	-f203	-0.186	0.010	f180,993	Zoledronic acid		
No gen. mortality	f6343	f4381	-0.970	0.035	f180,337	f124,558	f1757	-f205	-0.188	0.008	f208,454	Zoledronic acid		
5-year horizon	f6185	f4287	-0.895	0.032	f192,083	f133,134	f1714	-f185	-0.172	0.008	f223,148	Zoledronic acid		

Breast	BSC		BSC		BSC		BSC		Zoledronic acid		Zoledronic acid		Zoledronic acid	
	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS
2-year horizon	£4902	£3441	-0.585	0.020	£250,927	£176,109	£1355	-£106	-0.109	0.005	£292,125	£292,125		
vd Hout utility	£6308	£4358	-0.962	0.032	£196,932	£136,052	£1747	-£203	-0.186	0.008	£227,647	£227,647		
SAE P1+	£6308	£4358	-0.962	0.033	£189,253	£130,747	£1747	-£203	-0.186	0.014	£124,016	£124,016		
No SAE	£6344	£4367	-0.974	0.036	£178,058	£122,590	£1814	-£162	-0.189	0.007	£242,829	£242,829		
No gen. discs.	£11,657	£8075	-1.750	0.056	£208,350	£144,337	£3251	-£331	-0.344	0.014	£231,276	£231,276		
No discs.	£11,913	£8253	-1.788	0.057	£209,438	£145,104	£3323	-£336	-0.351	0.014	£232,177	£232,177		
TTF form AG naive	£6297	£4347	-0.971	0.036	£177,244	£122,356	£1748	-£202	-0.186	0.008	£208,080	£208,080		
TTF form AG all	£6148	£4198	-1.083	0.039	£155,959	£106,487	£1713	-£237	-0.213	0.009	£181,811	£181,811		

Univariate sensitivity analyses: prostate cancer

Prostate	BSC		BSC		BSC		BSC		Zoledronic acid		Zoledronic acid		Zoledronic acid	
	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS
All patients														
Base case	£3951	£2766	-0.543	0.035	£112,415	£78,713	£1059	-£125	-0.130	0.009	£111,603	Dominant		
Amgen STARS	£4179	£2995	-0.543	0.035	£118,915	£85,213	£1106	-£79	-0.130	0.009	£116,525	Dominant		
Amgen NMA	£3948	£2764	-0.546	0.035	£111,558	£78,091	£1060	-£124	-0.129	0.009	£112,659	Dominant		
Amgen STARS+NMA	£4177	£2993	-0.546	0.035	£118,030	£84,563	£1107	-£78	-0.129	0.009	£117,594	Dominant		
No naive util step	£3951	£2766	-0.543	0.026	£153,522	£107,497	£1059	-£125	-0.130	0.007	£159,704	Dominant		
SCC ongoing mean	£3951	£2766	-0.543	0.046	£85,204	£59,660	£1059	-£125	-0.130	0.012	£86,925	Dominant		
SCC ongoing max.	£3951	£2766	-0.543	0.054	£73,053	£51,152	£1059	-£125	-0.130	0.014	£75,460	Dominant		
No gen. mortality	£4037	£2825	-0.560	0.036	£110,722	£77,494	£1081	-£131	-0.134	0.010	£109,732	Dominant		
5-year horizon	£3941	£2761	-0.537	0.035	£113,896	£79,787	£1057	-£123	-0.129	0.009	£113,427	Dominant		
2-year horizon	£3591	£2524	-0.454	0.028	£127,528	£89,659	£973	-£93	-0.109	0.008	£129,289	Dominant		
vd Hout utility	£3951	£2766	-0.543	0.031	£128,929	£90,277	£1059	-£125	-0.130	0.008	£127,983	Dominant		

Prostate	BSC		BSC		BSC		BSC		Zoledronic acid		Zoledronic acid		Zoledronic acid	
	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	SREs	QALYs
SRE naive	£3969	£2785	-0.528	0.039	£103,003	£72,269	£1061	-£123	-0.129	0.011	£99,561	Dominant	-0.129	0.011
Base case	£4195	£3010	-0.528	0.039	£108,848	£78,114	£1107	-£77	-0.129	0.011	£103,929	Dominant	-0.129	0.011
Amgen STARs	£3965	£2780	-0.532	0.039	£101,900	£71,460	£1062	-£122	-0.128	0.011	£100,547	Dominant	-0.128	0.011
Amgen STARs+NMA	£4191	£3007	-0.532	0.039	£107,716	£77,276	£1108	-£76	-0.128	0.011	£104,926	Dominant	-0.128	0.011
No naive util step	£3969	£2785	-0.528	0.026	£153,733	£107,862	£1061	-£123	-0.129	0.007	£156,150	Dominant	-0.129	0.007
SCC ongoing mean	£3969	£2785	-0.528	0.049	£80,415	£56,420	£1061	-£123	-0.129	0.013	£79,802	Dominant	-0.129	0.013
SCC ongoing max.	£3969	£2785	-0.528	0.057	£69,884	£49,032	£1061	-£123	-0.129	0.015	£70,226	Dominant	-0.129	0.015
No gen. mortality	£4054	£2843	-0.546	0.040	£101,176	£70,945	£1082	-£129	-0.133	0.011	£97,612	Dominant	-0.133	0.011
5-year horizon	£3961	£2781	-0.520	0.038	£104,689	£73,497	£1060	-£120	-0.126	0.010	£101,544	Dominant	-0.126	0.010
2-year horizon	£3620	£2553	-0.429	0.030	£120,521	£85,018	£99	-£88	-0.105	0.008	£119,210	Dominant	-0.105	0.008
vd Hou utility	£3969	£2785	-0.528	0.034	£118,235	£82,955	£1061	-£123	-0.129	0.009	£114,266	Dominant	-0.129	0.009
SAE P1+	£3969	£2785	-0.528	0.024	£162,306	£113,877	£1061	-£123	-0.129	0.011	£95,272	Dominant	-0.129	0.011
No SAE	£3983	£2773	-0.540	0.042	£95,819	£66,716	£1083	-£126	-0.136	0.011	£95,462	Dominant	-0.136	0.011
No gen. discs.	£7571	£5312	-1.037	0.068	£111,073	£77,935	£2020	-£239	-0.239	0.018	£109,544	Dominant	-0.239	0.018
No discs.	£7875	£5526	-1.081	0.071	£111,674	£78,358	£2208	-£142	-0.265	0.020	£111,053	Dominant	-0.265	0.020
TTF form AG naive	£3993	£2809	-0.507	0.037	£107,860	£75,867	£1069	-£116	-0.122	0.010	£105,215	Dominant	-0.122	0.010
TTF form AG all	£3953	£2769	-0.541	0.040	£100,060	£70,085	£1057	£128	-0.132	0.011	£96,521	Dominant	-0.132	0.011

Univariate sensitivity analyses: other solid tumours plus non-small cell lung cancer

OST + NSCLC	BSC		Zoledronic acid							
	Excluding PAS	Including PAS	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
All patients										
Base case	f2548	£1766	£147,122	£101,986	£836	£54	-0.092	0.006	£139,739	£9004
Amgen STARs	f2676	£1894	£154,479	£109,343	£859	£78	-0.092	0.006	£143,729	£12,994
Amgen NMA	f2567	£1786	£156,113	£108,578	£837	£56	-0.091	0.006	£141,762	£9432
Amgen STARs+NMA	f2690	£1909	£163,599	£116,063	£861	£79	-0.091	0.006	£145,729	£13,399
No naive util step	f2548	£1766	£175,401	£121,589	£836	£54	-0.092	0.005	£162,929	£10,498
SCC ongoing mean	f2548	£1766	£126,620	£87,774	£836	£54	-0.092	0.007	£120,980	£7795
SCC ongoing max.	f2548	£1766	£113,410	£78,617	£836	£54	-0.092	0.008	£108,775	£7008
No gen. mortality	f2557	£1772	£146,781	£101,744	£839	£54	-0.093	0.006	£139,429	£9057
5-year horizon	f2548	£1767	£148,914	£103,282	£834	£54	-0.091	0.006	£141,622	£9121
2-year horizon	f2443	£1698	£156,692	£108,877	£781	£36	-0.083	0.005	£148,731	£6827
vd Hour utility	f2548	£1766	£177,567	£123,091	£836	£54	-0.092	0.005	£168,010	£10,825
SAE P1+	f2548	£1766	£188,601	£130,740	£836	£54	-0.092	0.010	£87,426	£5633
No SAE	f2535	£1747	£139,278	£95,988	£834	£46	-0.093	0.006	£143,426	£7867
No gen. discs.	f6004	£4173	£157,753	£109,654	£1619	£211	-0.183	0.012	£138,680	Dominant
No discs.	f6150	£4275	£158,204	£109,980	£1686	£189	-0.190	0.012	£139,541	Dominant
TTF form AG naive	-	-	-	-	-	-	-	-	-	-
TTF form AG all	f2549	£1767	£147,049	£101,951	£838	£56	-0.090	0.006	£142,626	£9591

SRE naive	OST + NSCLC						BSC						Zoledronic acid					
	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including	Excluding PAS	Including PAS	SREs	QALYs	ICER excluding	ICER including
Base case	£2473	£1691	-0.343	0.024	£103,350	£70,679	£823	£41	-0.103	0.008	£106,812	£5337	£823	£41	-0.103	0.008	£106,812	£5337
Amgen STARs	£2618	£1836	-0.343	0.024	£109,409	£76,737	£850	£68	-0.103	0.008	£110,310	£8834	£850	£68	-0.103	0.008	£110,310	£8834
Amgen NMA	£2509	£1727	-0.320	0.022	£112,789	£77,644	£825	£43	-0.102	0.008	£108,515	£5702	£825	£43	-0.102	0.008	£108,515	£5702
Amgen STARs+NMA	£2646	£1864	-0.320	0.022	£118,943	£83,798	£852	£70	-0.102	0.008	£111,992	£9179	£852	£70	-0.102	0.008	£111,992	£9179
No naive util step	£2473	£1691	-0.343	0.018	£135,660	£92,775	£823	£41	-0.103	0.006	£137,904	£6890	£823	£41	-0.103	0.006	£137,904	£6890
SCC ongoing mean	£2473	£1691	-0.343	0.027	£90,853	£62,132	£823	£41	-0.103	0.009	£94,286	£4711	£823	£41	-0.103	0.009	£94,286	£4711
SCC ongoing max.	£2473	£1691	-0.343	0.030	£82,514	£56,429	£823	£41	-0.103	0.010	£85,870	£4290	£823	£41	-0.103	0.010	£85,870	£4290
No gen. mortality	£2481	£1696	-0.344	0.024	£103,033	£70,452	£826	£42	-0.104	0.008	£106,469	£5359	£826	£42	-0.104	0.008	£106,469	£5359
5-year horizon	£2476	£1695	-0.338	0.024	£105,289	£72,086	£823	£42	-0.101	0.008	£109,190	£5606	£823	£42	-0.101	0.008	£109,190	£5606
2-year horizon	£2385	£1639	-0.311	0.021	£113,714	£78,167	£775	£29	-0.090	0.007	£118,569	£4448	£775	£29	-0.090	0.007	£118,569	£4448
vd Hou utility	£2473	£1691	-0.343	0.020	£124,310	£85,013	£823	£41	-0.103	0.006	£127,857	£6388	£823	£41	-0.103	0.006	£127,857	£6388
SAE P1+	£2473	£1691	-0.343	0.020	£122,918	£84,061	£823	£41	-0.103	0.011	£72,937	£3644	£823	£41	-0.103	0.011	£72,937	£3644
No SAE	£2459	£1671	-0.345	0.025	£98,978	£67,269	£821	£33	-0.104	0.008	£108,627	£4347	£821	£33	-0.104	0.008	£108,627	£4347
No gen. discs.	£5895	£4064	-0.760	0.049	£120,402	£83,010	£1608	£222	-0.194	0.014	£113,154	Dominant	£1608	£222	-0.194	0.014	£113,154	Dominant
No discs.	£6040	£4165	-0.777	0.050	£121,082	£83,502	£1675	£200	-0.202	0.015	£114,173	Dominant	£1675	£200	-0.202	0.015	£114,173	Dominant
TTF form AG naive	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
TTF form AG all	£2475	£1693	-0.339	0.024	£103,297	£70,666	£828	£46	-0.099	0.007	£110,506	£6173	£828	£46	-0.099	0.007	£110,506	£6173

Probabilistic modelling

Breast cancer: all patients

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.822	CiC information has been removed	0.028	£4269	£154,944
Zoledronic acid	1.842	CiC information has been removed	0.007	-£243	Dominant
Denosumab	1.849	CiC information has been removed	-	-	-
Disodium pamidronate	1.840	CiC information has been removed	0.010	-£3246	Dominant

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate
£0	92%	8%	0%
£20,000	98%	2%	0%
£30,000	100%	0%	0%
£40,000	100%	0%	0%
£100,000	100%	0%	0%

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate	BSC
£0	0%	0%	0%	100%
£20,000	0%	0%	0%	100%
£30,000	0%	0%	0%	100%
£40,000	0%	0%	0%	100%
£100,000	13%	0%	0%	87%




FIGURE 16 Breast cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 16 Breast cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. *(continued)*

Prostate cancer: all patients

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.065	CiC information has been removed	0.035	£2764	£78,756
Zoledronic acid	1.091	CiC information has been removed	0.009	-£123	Dominant
Denosumab	1.100	CiC information has been removed	-	-	-

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	88%	12%
£20,000	99%	1%
£30,000	100%	0%
£40,000	100%	0%
£100,000	100%	0%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	2%	0%	98%
£100,000	73%	0%	27%






FIGURE 17 Prostate cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 17 Prostate cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Other solid tumours plus non-small cell lung cancer: all patients

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.701	CiC information has been removed	0.017	£1771	£102,102
Zoledronic acid	0.713	CiC information has been removed	0.006	£56	£9391
Denosumab	0.719	CiC information has been removed	–	–	–

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	26%	75%
£20,000	75%	25%
£30,000	88%	12%
£40,000	93%	7%
£100,000	99%	1%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	1%	0%	99%
£100,000	44%	0%	56%




FIGURE 18 Other solid tumour plus NSCLC: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 18 Other solid tumour plus NSCLC: all patients. (a) Cost-effectiveness acceptability curves (CEACs excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Non-small cell lung cancer: all patients

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.439	CiC information has been removed	0.012	£1582	£132,177
Zoledronic acid	0.446	CiC information has been removed	0.005	£32	£6967
Denosumab	0.451	CiC information has been removed	–	–	–

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	35%	65%
£20,000	69%	31%
£30,000	77%	23%
£40,000	82%	18%
£100,000	91%	9%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	1%	0%	99%
£100,000	27%	1%	73%




FIGURE 19 Non-small cell lung cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 19 Non-small cell lung cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Breast cancer: skeletal-related event naive

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.848	CiC information has been removed	0.035	£4340	£124,461
Zoledronic acid	1.875	CiC information has been removed	0.008	-£204	Dominant
Denosumab	1.883	CiC information has been removed	-	-	-
Disodium pamidronate	1.873	CiC information has been removed	0.009	-£3109	Dominant

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate
£0	88%	12%	0%
£20,000	98%	2%	0%
£30,000	99%	1%	0%
£40,000	99%	1%	0%
£100,000	100%	0%	0%

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate	BSC
£0	0%	0%	0%	100%
£20,000	0%	0%	0%	100%
£30,000	0%	0%	0%	100%
£40,000	1%	0%	0%	99%
£100,000	26%	0%	0%	74%




FIGURE 20 Breast cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 20 Breast cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Prostate cancer: skeletal-related event naive

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.088	CiC information has been removed	0.039	£2786	£71,920
Zoledronic acid	1.116	CiC information has been removed	0.011	-£121	Dominant
Denosumab	1.126	CiC information has been removed	-	-	-

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	86%	14%
£20,000	99%	1%
£30,000	99%	1%
£40,000	99%	1%
£100,000	100%	0%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	3%	0%	97%
£100,000	81%	0%	19%






FIGURE 21 Prostate cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 21 Prostate cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Other solid tumours plus non-small cell lung cancer: skeletal-related event naive

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.715	CiC information has been removed	0.024	£1702	£71,883
Zoledronic acid	0.731	CiC information has been removed	0.008	£45	£5848
Denosumab	0.739	CiC information has been removed	–	–	–

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	31%	69%
£20,000	84%	16%
£30,000	93%	7%
£40,000	96%	4%
£100,000	99%	1%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	1%	0%	99%
£40,000	6%	0%	94%
£100,000	76%	0%	24%






FIGURE 22 Other solid tumour plus NSCLC: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 22 Other solid tumour plus NSCLC: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Non-small cell lung cancer: skeletal-related event naive

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.453	CiC information has been removed	0.014	£1578	£109,934
Zoledronic acid	0.461	CiC information has been removed	0.006	£16	£2620
Denosumab	0.467	CiC information has been removed	–	–	–

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	44%	56%
£20,000	75%	25%
£30,000	80%	20%
£40,000	83%	17%
£100,000	90%	10%

WTP/QALY	DEN	ZOL	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	2%	0%	98%
£100,000	42%	1%	57%




FIGURE 23 Non-small cell lung cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 23 Non-small cell lung cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Breast cancer: skeletal-related event experienced

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	1.778	CiC information has been removed	0.017	£4146	£241,181
Zoledronic acid	1.790	CiC information has been removed	0.005	-£298	Dominant
Denosumab	1.795	CiC information has been removed	-	-	-
Disodium pamidronate	1.785	CiC information has been removed	0.010	-£3470	Dominant

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate
£0	94%	6%	0%
£20,000	98%	2%	0%
£30,000	99%	1%	0%
£40,000	99%	1%	0%
£100,000	100%	0%	0%

WTP/QALY	Denosumab	Zoledronic acid	Disodium pamidronate	BSC
£0	0%	0%	0%	100%
£20,000	0%	0%	0%	100%
£30,000	0%	0%	0%	100%
£40,000	1%	0%	0%	99%
£100,000	7%	0%	0%	94%






FIGURE 24 Breast cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 24 Breast cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)

Prostate cancer: skeletal-related event experienced

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.996	CiC information has been removed	0.027	£2695	£101,216
Zoledronic acid	1.017	CiC information has been removed	0.006	-£132	Dominant
Denosumab	1.023	CiC information has been removed	-	-	-

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	86%	14%
£20,000	97%	3%
£30,000	98%	2%
£40,000	99%	1%
£100,000	99%	1%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	1%	0%	100%
£40,000	2%	0%	98%
£100,000	44%	1%	56%




FIGURE 25 Prostate cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 25 Prostate cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Other solid tumours plus non-small cell lung cancer: skeletal-related event experienced

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.689	CiC information has been removed	0.011	£1825	£159,757
Zoledronic acid	0.696	CiC information has been removed	0.004	£63	£14,373
Denosumab	0.700	CiC information has been removed	–	–	–

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	26%	74%
£20,000	59%	41%
£30,000	71%	29%
£40,000	80%	20%
£100,000	94%	6%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	0%	0%	100%
£100,000	14%	0%	86%






FIGURE 26 Other solid tumour: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 26 Other solid tumour: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)

Non-small cell lung cancer: skeletal-related event experienced

	QALY	£ total	Δ QALY	Δ Cost	ICER
BSC	0.425	CiC information has been removed	0.010	£1572	£157,231
Zoledronic acid	0.432	CiC information has been removed	0.003	£41	£12,415
Denosumab	0.435	CiC information has been removed	–	–	–

CiC, commercial-in-confidence.

WTP/QALY	Denosumab	Zoledronic acid
£0	33%	67%
£20,000	59%	41%
£30,000	66%	34%
£40,000	72%	28%
£100,000	84%	16%

WTP/QALY	Denosumab	Zoledronic acid	BSC
£0	0%	0%	100%
£20,000	0%	0%	100%
£30,000	0%	0%	100%
£40,000	1%	0%	99%
£100,000	20%	1%	79%






FIGURE 27 Non-small cell lung cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC.




FIGURE 27 Non-small cell lung cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (*continued*)